Skip to main content
Premium Trial:

Request an Annual Quote

Somalogic, U of Leeds Partnering on Personalized Medicine Initiative

NEW YORK (GenomeWeb) – Somalogic said today it has established a collaboration with the Leeds Centre for Personalised Medicine and Health to investigate the ability of protein measurements to impact patient care in a variety of clinical areas.

The partners will use Somalogic's SomaScan proteomic platform, which uses the company's aptamer-based affinity reagents called Somamers to measure large numbers of proteins in patient samples, typically blood. Somalogic currently offers a SomaScan panel covering roughly 1,300 proteins from its CLIA lab, and plans to begin offering a 5,000-plex version out of its CLIA facility in the second quarter of this year.

The Leeds collaboration is part of a larger move by the company to develop SomaScan as a clinical tool.

"This partnership has the potential to deliver huge benefits for the people of Leeds, in terms of better health outcomes and more efficient use of health and care resources," Mike Messenger, head of the Leeds CPMH, said in a statement.

"Leeds CPMH is at the forefront of integrating academia, industry, healthcare providers, and individual citizens to go beyond the ‘one size fits all’ approach to healthcare,” added Somalogic Chief Medical Officer Steve Williams. “We are thrilled that Leeds CPMH is the first of what we trust will be many test-bed partners around the world."

Financial and other terms of the agreement were not disclosed.